Showing results (261-270 of 315) with videos related to

Sort By:
Pageof 32
European Journal of Clinical Investigation|June 19, 2025
Incretin system and glucagon secretion in patients with chronic pancreatitisGea Ciccarelli, Gianfranco Di Giuseppe, Giulia Gliozzo, et al.
Nature Communications|January 15, 2026
Microbial activation of the GLP-2R mitigates gastrointestinal inflammationSune K Yang-Jensen, Béatrice S-Y Choi, Nora S Nägele, et al.
The Lancet. Diabetes & Endocrinology|May 22, 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialMads M Helsted, Christiane Fonnesbech-Wulff, Nina L Schaltz, et al.
Diabetologia|January 7, 2022
Dietary carbohydrate restriction augments weight loss-induced improvements in glycaemic control and liver fat in individuals with type 2 diabetes: a randomised controlled trialMads N Thomsen, Mads J Skytte, Amirsalar Samkani, et al.
Diabetologia|July 3, 2017
Why is it so difficult to measure glucagon-like peptide-1 in a mouse?Johanne A Windeløv, Nicolai J Wewer Albrechtsen, Rune E Kuhre, et al.
The Journal of Clinical Endocrinology and Metabolism|May 12, 2025
Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in HumansGianfranco Di Giuseppe, Giulia Gliozzo, Gea Ciccarelli, et al.
Clinical Nutrition (Edinburgh, Scotland)|June 9, 2022
Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trialNicole Jacqueline Jensen, Helena Zander Wodschow, Mads Juul Skytte, et al.
Diabetes, Obesity & Metabolism|February 13, 2023
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motilityHenriette H Nerild, Andreas Brønden, Ida M Gether, et al.
Eclinicalmedicine|March 2, 2026
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trialCasper K Nielsen, Thorir G Pálsson, Julie L Forman, et al.
Diabetes, Obesity & Metabolism|March 10, 2026
Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover StudyIda M Gether, Vivian Kliim-Hansen, Petur T Olafsson, et al.
Pageof 32